BAY987517
PreclinicalSmall molecule
BayerBAY987517 is one of 106 small molecule programs targeting Allergy. It is currently in Preclinical.
5
Indications
16
Total Trials
0
Active Trials
105
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
127 competitors in Adult
#DrugCompanyPhaseTrials
1Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Mounjaro
Eli LillyPhase 2
Rifampicin
Boehringer IngelheimPhase 3
Myqorzo
CCytokinetics
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 2
Skyclarys
BiogenPhase 1
Sunlenca
GileadPhase 1
NM8074
NNovelMed Therapeutics
Phase 2
EB-1020
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Exercise2 trials
1 more indication
Unspecified9 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BAY987517. EMBL-EBI & Wellcome Sanger Institute.
- [4]